The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling

Psychopharmacology

Volumn 227, Issue 4, 2013, Pages 711-725

  Wierońska, Joanna M ^a   Acher, Francine C ^b   Sławińska, Anna ^a   Gruca, Piotr ^a   Łasoń Tyburkiewicz, Magdalena ^a   Papp, Mariusz ^a   Pilc, Andrzej ^a,c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Amphetamine; Animal model; Antipsychotic; Behavior; Glutamate; Metabotropic glutamate receptor; MK 801; Object recognition; Schizophrenia; Serotonin receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE; DIZOCILPINE; LSP 1 2111; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; HABITUATION; HEAD TWITCH; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; RECOGNITION; SIGNAL TRANSDUCTION; SOCIAL INTERACTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMINOBUTYRATES; AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; CYCLOHEXANES; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; PHOSPHINIC ACIDS; PIPERAZINES; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 84878711236     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3005-0     Document Type: Article

References (66)

1. Acher FC, Tellier FJ, Azerad R, Brabet IN, Fagni L, Pin JP (1997) Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem 40(19):3119-3129
2. Acher F, Selvam C, Triballeau N, Pin JP, Bertrand HO (2007) Hypo-phosphorous acid derivatives and their therapeutical applications. U.S. Patent Application WO2007052169
3. Ago Y, Koyama Y, Baba A, Matsuda T (2003) Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 45(8):1050-1056
4. Allen AR, Singh A, Zhuang ZP, Kung MP, Kung HF, Lucki I (1997) The 5-HT1A receptor antagonist p-MPPI blocks responses mediated by postsynaptic and presynaptic 5-HT1A receptors. Pharmacol Biochem Behav 57(1-2):301-307
5. Alphs L, Benedetti F, Fleischhacker WW, Kane JM (2012) Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 15(7):1003-1014
6. Amitai N, Markou A (2010) Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. Eur J Pharmacol 639(1-3):67-80
7. Andlin-Sobocki P, Rössler W (2005) Cost of psychotic disorders in Europe. Eur J Neurol 12(Suppl 1):74-77
8. Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonist. Trends Neurosci 19(9):378-383
9. Barak S, Weiner I (2011) Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Pharmacol Biochem Behav 99(2):164-189
10. Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083-1152
11. Beurrier C, Lopez S, Révy D, Selvam C, Goudet C, Lhérondel M, Gubellini P, Kerkerian-LeGoff L, Acher F, Pin JP, Amalric M (2009) Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 23(10):3619-3628
12. Blanchard RJ, Griebel G, Guardiola-Lemaître B, Brush MM, Lee J, Blanchard DC (1997) An ethopharmacological analysis of selective activation of 5-HT1A receptors: the mouse 5-HT1A syndrome. Pharmacol Biochem Behav 57(4):897-908
13. Boulay D, Depoortre R, Louis C, Perrault G, Griebel G, Soubrié P (2004) SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46(8):1121-1129
14. Bubeníková-Valesová V, Votava M, Pálenícek T, Horácek J (2007) The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology 52(4):1071-1078
15. Burnet PW, Eastwood SL, Harrison PJ (1996) 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15(5):442-455
16. Cartmell J, Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75(3):889-907
17. Cartmell J, Monn JA, Schoepp DD (2000a) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berlin) 148(4):423-429
18. Cartmell J, Monn JA, Schoepp DD (2000b) The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400(2-3):221-224
19. Conn PJ, Lindsley CW, Jones CK (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30(1):25-31
20. Cramer P, Bowen J, O'Neill M (1992) Schizophrenics and social judgement. Why do schizophrenics get it wrong? Br J Psychiatry 160:481-487
21. Dall'Olio R, Gaggi R, Bonfante V, Gandolfi O (1999) The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol 10(1):63-71
22. Dere E, Huston JP, De Souza Silva MA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31(5):673-704
23. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLeachan A, Stanhope KJ, Critchley DJ, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Lapore AM, Gozlan H, Hamon M, Douris CT (1996) Electrophysiological, biochemical, neurohormonal and behavioral studies with WAY100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73:337-353
24. Flor PJ, Acher FC (2012) Orthosteric versus allosteric GPCR activation: the great challenge of group-III mGluRs. Biochem Pharmacol 84(4):414-424
25. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183):93-97
26. Goodwin GM, De Souza RJ, Wood AJ, Green AR (1986) The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berlin) 90(4):488-493
27. Goodwin GM, De Souza RJ, Green AR (1987) Attenuation by electroconvulsive shock and antidepressant drugs of the 5-HT1A receptor-mediated hypothermia and serotonin syndrome produced by 8-OH-DPAT in the rat. Psychopharmacology (Berlin) 91(4):500-505
28. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 18(6):448-454
29. Homberg JR, De Boer SF, Raas HS, Olivier JD, Verheul M, Ronken E, Cools AR, Ellenbroek BA, Schoffelmeer AN, Vanderschuren LJ, De Vries TJ, Cuppen E (2008) Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berlin) 200(3):367-380
30. Horiguchi M, Huang M, Meltzer HY (2011a) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338(2):605-614
31. Horiguchi M, Huang M, Meltzer HY (2011b) Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berlin) 217(1):13-24
32. Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956(2):349-357
33. Iijima M, Shimazaki T, Ito A, Chaki S (2007) Effects of metabotropic glutamate 2/3 receptor antagonists in the stress-induced hyperthermia test in singly housed mice. Psychopharmacology (Berlin) 190(2):233-239
34. Javitt DC (1987) Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9(1):12-35
35. Kanuma K, Aoki T, Shimazaki Y (2010) Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia. Recent Pat CNS Drug Discov 5(1):23-34
36. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N, the HBBI Study Group (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31(3):349-355
37. Larsson LG, Rényi L, Ross SB, Svensson B, Angeby-Möller K (1990) Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT. Neuropharmacology 29(2):85-91
38. Linden AM, Schoepp DD (2006) Metabotropic glutamate receptor targets for neuropsychiatric disorders. Drug Discov Today Ther Strateg 3:507-517
39. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292(1):76-87
40. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27(7):1159-1172
41. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL Jr, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD (1999) Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 42(6):1027-1040
42. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363(9426):2063-2072
43. Ohno Y (2011) Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 17(1):58-65
44. Olivier B, Zethof TJ, Ronken E, van der Heyden JA (1998) Anxiolytic effects of flesinoxan in the stress-induced hyperthermia paradigm in singly-housed mice are 5-HT1A mediated. Eur J Pharmacol 342:177-182
45. Olivier JD, Cools AR, Olivier B, Homberg JR, Cuppen E, Ellenbroek BA (2008) Stress-induced hyperthermia and basal body temperature are mediated by different 5-HT(1A) receptor populations: a study in SERT knockout rats. Eur J Pharmacol 590(1-3):190-197
46. Pałucha-Poniewiera A, Kłodzińska A, Stachowicz K, Tokarski K, Hess G, Schann S, Frauli M, Neuville P, Pilc A (2008) Peripheral administration of group III mGlu receptor agonist ACPT-I exerts potential antipsychotic effects in rodents. Neuropharmacology 55(4):517-524
47. Pałucha-Poniewiera A, Brański P, Lenda T, Pilc A (2010) The antidepressant-like action of metabotropic glutamate 7 receptor agonist N, N'-bis(diphenylmethyl)-1,2-ethanediamine (AMN082) is serotonin-dependent. J Pharmacol Exp Ther 334(3):1066-1074
48. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13(9):1102-1107
49. Pin JP, Duvoisin R (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34(1):1-26
50. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berlin) 193(1):121-136
51. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A, Matsuda T (2000) Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129(5):1028-1034
52. Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H (2009) Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol- 4-yl]-2,3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther 330(1):179-190
53. Simpson MD, Lubman DI, Slater P, Deakin JF (1996) Autoradiography with [3H](R)-(+)-8-Hydroxy-DPAT hydrobromide reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 39(11):919-928
54. Sławińska A, Wieronska JM, Stachowicz K, Łasoń-Tyburkiewicz M, Gruca P, Papp M, Kusek M, Tokarski K, Doller D, Pilc A (2013) The antipsychotic-like effects of mGlu4 receptor positive allosteric modulators in rodents. JPET, submitted
55. Stachowicz K, Kłodzińska A, Palucha-Poniewiera A, Schann S, Neuville P, Pilc A (2009) The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology 57(3):227-234
56. Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Hutson PH (2009) Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology (Berlin) 206(4):641-651
57. Vinkers CH, de Jong NM, Kalkman CJ, Westphal KG, van Oorschot R, Olivier B, Korte SM, Groenink L (2009) Stress-induced hyperthermia is reduced by rapid-acting anxiolytic drugs independent of injection stress in rats. Pharmacol Biochem Behav 93(4):413-418
58. Wedzony K, Maćkowiak M, Zajaczkowski W, Fijał K, Chocyk A, Czyrak A (2000) WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology 23(5):547-559
59. Wedzony K, Chocyk A, Maćkowiak M (2008) A search for colocalization of serotonin 5-HT2A and 5-HT1A receptors in the rat medial prefrontal and entorhinal cortices - immunohistochemical studies. J Physiol Pharmacol 59(2):229-238
60. Weinberger DR (2007) Schizophrenia drug says goodbye to dopamine. Nat Med 13(9):1018-1019
61. Wierońska JM, Stachowicz K, Pałucha-Poniewiera A, Acher F, Brański P, Pilc A (2010) Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 59(7-8):627-634
62. Wierońska JM, Kusek M, Tokarski K, Wabno J, Froestl W, Pilc A (2011) The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioral changes related to positive syndromes of psychosis in mice. Br J Pharmacol 163(5):1034-1047
63. Wierońska JM, Stachowicz K, Brański P, Pałucha- Poniewiera A, Pilc A (2012a) On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice. Neuropharmacology 62(1):322-331
64. Wierońska JM, Stachowicz K, Acher F, Lech T, Pilc A (2012b) Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia. Psychopharmacology (Berlin) 220(3):481-494
65. Wood M, Chaubey M, Atkinson P, Thomas DR (2000) Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor.Eur. J Pharmacol 396(1):1-8
66. Yu H, Lewander T (1997) Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur Neuropsychopharmacol 7(3):165-172